Who
Rita Jain
Director
Company insider
Files Form 4 as: Director, Avalo Therapeutics; Director, Celldex Therapeutics; Director, First Tracks Biotherapeutics; Director, AnaptysBio; Director, SAB Biotherapeutics; Director, Provention Bio; EVP, Chief Medical Officer, ChemoCentryx; Chief Medical Officer, Immunovant.
In numbers
- Trades disclosed
- 110
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 31 May 2017
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $16K1,322 at $12.29 | filing |
| 30 Jun 2026filed 2 Jul 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $16K1,080 at $15.04 | filing |
| 30 Jun 2026filed 2 Jul 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $16K1,080 at $15.04 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —7,330 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,300 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,300 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —7,330 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.